| Literature DB >> 31412833 |
Zhengyang Yang1, Feng Sun1, Shichao Ai1, Jiafeng Wang1, Wenxian Guan2, Song Liu3.
Abstract
BACKGROUND: Appendectomy is considered the first treatment choice for appendicitis. However, controversy exists since conservative therapy is associated with fewer complications than appendectomy for patients with acute appendicitis (AA). This meta-analysis aimed to compare the outcomes between conservative therapy and appendectomy in the management of adult AA.Entities:
Keywords: Adult acute appendicitis; Appendectomy; Conservative treatment; Meta-analysis
Mesh:
Substances:
Year: 2019 PMID: 31412833 PMCID: PMC6694559 DOI: 10.1186/s12893-019-0578-5
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.102
Fig. 1Flow chart of study selection
Brief information of the included studies
| First author | Eriksson S | Oliak D | Tingstedt B | Styrud J | Liu K | Hansson J | Turhan A | Vons C | Hansson J | Mentula P | Salminen P |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | 1995 | 2001 | 2002 | 2006 | 2007 | 2009 | 2009 | 2011 | 2012 | 2015 | 2015 |
| Journal | Br J Surg | Dis | Eur J Surg | World J Surg | Am Surg | Br J Surg | Ulus Travma Acil Cerrahi Derg | Lancet | World J Surg | Ann Surg | JAMA |
| Region | Sweden | USA | Sweden | Sweden | USA | Sweden | Turkey | France | Sweden | Finland | Finland |
| Study type | Prospective controlled | Retrospective | Retrospective | Multicentre RCT | Retrospective | Multicentre RCT | Prospective controlled | Multicentre RCT | Prospective nonrandomized | Single centre RCT | Multicentre RCT |
| No. conservative group | 20 | 88 | 50 | 128 | 19 | 202 | 107 | 120 | 442 | 30 | 257 |
| No. surgery group | 20 | 67 | 43 | 124 | 51 | 167 | 183 | 119 | 111 | 30 | 273 |
| Patient type | Mixed | Periappendiceal abscess | Periappendiceal abscess | Mixed | Uncomplicated | Mixed | Mixed | Uncomplicated | Mixed | Periappendiceal abscess | Uncomplicated |
| Antibiotic strategy | (cefotaxime 2 g bid + tinidazole 0.8 g qd) iv 2d + (ofloxacin 0.2 g bid + tinidazole 0.5 g bid) po 8d | iv administration, N/A | (cephalosporin + metronidazole OR imipenem) iv + (cephalosporin + metronidazole) po | (cefotaxime 2 g bid + tinidazole 0.8 g qd) iv 2d + (ofloxacin 0.2 g bid + tinidazole 0.5 g bid) po 10d | iv 1-6d + po 7-14d | (cefotaxime 1 g bid + metronidazole 1.5 g qd) iv 1d + (ciprofloxacin 0.5 g bid + metronidazole 0.4 g tid) po 10d | (ampicillin 1 g qid + gentamicin 160 mg qd + metronidazole 0.5 g tid) iv 3d + N/A po 7d | amoxicillin/clavulanic acid (3 g/d if BW < 90 kg, 4 g/d if BW > 90 kg), iv OR po | (piperacillin/tazobactam 4 g tid) iv 1d + (ciprofloxacin 0.5 g + metronidazole 400 mg bid) po 9d | (cefuroxime 1.5 g tid + metronidazole 0.5 g qd) iv + (cephalexin 0.5 g tid + metronidazole 0.5 g tid) po 7d | (ertapenem 1 g qd) iv 3d + (levofloxacin 0.5 g qd + metronidazole 0.5 g tid) po 7d |
| Other conservative strategy | N/A | PCD selectively, if not improve in 72 h will receive appendectomy | PCD (18%, 9/50) | if not improve in 24 h will receive appendectomy | N/A | N/A | N/A | if not improve in 48 h will receive appendectomy | if not improve in 24–48 h will receive appendectomy | PCD if abscess> 3 cm | N/A |
| Conflict of Interests | Swedish Hoechst AB, Pfizer AB, Mutual Group Life Insurance Company ‘Forenade Liv’ | N/A | N/A | Wallenius Corporation, Aventis Pharma | N/A | None | N/A | None | None | None | Merck, Roche |
Risk-of-bias summary of randomized clinical trials
| Reference | Styrud J 2006 | Hansson J 2009 | Vons C 2011 | Mentula P 2015 | Salminen P 2015 |
|---|---|---|---|---|---|
| Random sequence generation | + | + | + | + | + |
| Allocation concealment | + | + | + | + | + |
| Blinding of participants and personnel | – | – | – | – | – |
| Blinding of outcome assessment | – | + | + | + | + |
| Incomplete outcome data | – | + | + | + | / |
| Selective reporting | / | / | / | / | / |
| Other bias | / | / | / | / | / |
+: low risk of bias
-: high risk of bias
/: unclear risk of bias
Methodological quality criteria in retrospective studies
| Reference | Oliak D 2001 | Tingstedt B 2002 | Liu K 2007 |
|---|---|---|---|
| Patient selection | |||
| Definition adequate | 1 | 1 | 1 |
| Representativeness | 1 | 1 | 1 |
| Selection of controls | 0 | 0 | 0 |
| Definition of controls | 1 | 1 | 1 |
| Comparability | |||
| Most important factor | 1 | 1 | 1 |
| Other additional factor | 0 | 0 | 0 |
| Exposure | |||
| Ascertainment of exposure | 1 | 0 | 0 |
| Same method of ascertainment for cases and controls | 1 | 1 | 1 |
| Non-response rate | 0 | 0 | 0 |
| Aggregate score | 6 | 5 | 5 |
Methodological quality criteria in prospective controlled studies
| Reference | Eriksson S 1995 | Turhan A 2009 | Hansson J 2012 |
|---|---|---|---|
| Patient selection | |||
| Representativeness | 1 | 1 | 1 |
| Selection of the non-exposed cohort | 1 | 1 | 1 |
| Ascertainment of exposure | 0 | 1 | 1 |
| Demonstration that outcome of interest was not present at start of study | 1 | 0 | 1 |
| Comparability | |||
| Most important factor | 1 | 1 | 1 |
| Other additional factor | 0 | 0 | |
| Outcome | |||
| Assessment | 0 | 0 | 1 |
| Follow-up long enough for outcomes to occur | 0 | 1 | 1 |
| Adequacy of follow-up | 1 | 1 | 0 |
| Aggregate score | 5 | 6 | 7 |
Fig. 2Forest plot showing the effective rate of both conservative and appendectomy treatments in the three subgroups: mixed population, uncomplicated population and complicated population
Fig. 3Forest plot showing the complication rate of both conservative and appendectomy treatments in the three subgroups: mixed population, uncomplicated population and complicated population
Fig. 4Forest plot showing the reoperation rate of both conservative and appendectomy treatments in the three subgroups: mixed population, uncomplicated population and complicated population
Fig. 5Forest plot showing the length of stay of both conservative and appendectomy treatments in the three subgroups: mixed population, uncomplicated population and complicated population